PI3K Inhibition in Hematologic Malignancies

Video

For High-Definition, Click

Treatment with the oral PI3K-delta inhibitor idelalisib produced an overall response rate of 57% with average response duration of 12.5 months in heavily pretreated patients with indolent non-Hodgkin’s lymphoma (iNHL). This promising benefit was seen in a single-agent, phase II study that involved 125 patients with various types of iNHL, including follicular lymphoma (72 patients), small lymphocytic lymphoma (28), marginal-zone lymphoma (15), and lymphoplasmacytic lymphoma with or without Waldenström’s macroglobulinemia (10), explains Brad S. Kahl, MD.

Based on these data, the FDA has accepted a new drug application for idelalisib for the treatment of patients with iNHL. A target review date under the Prescription Drug User Fee Act was set for September 11, 2014.

The PI3K-delta and gamma inhibitor IPI-145 has also shown promising activity in patients with chronic lymphocytic leukemia (CLL) and T-cell lymphomas, notes John C. Byrd, MD. It appears that lymphocytosis resolves sooner with IPI-145 than it does with ibrutinib. Although the follow-up of the phase I study exploring the drug is shorter, the toxicity in patients with CLL appears manageable, Byrd notes.

Related Videos
Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center
Jennifer Brown, MD, PhD
Dipti Patel-Donnelly, MD, Johns Hopkins
Saad J. Kenderian, MB, CHB
Jasmin M. Zain, MD
Andrew Ip, MD
Sagar S. Patel, MD